Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

37.16 +0.54 (+1.46%)
Streaming Delayed Price Updated: 10:00 AM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
38 39 Next >
Price Over Earnings Overview: GSK
Via Benzinga
Looking Into GSK's Recent Short Interest
Via Benzinga
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
A panel of advisors to the Food and Drug Administration (FDA) reportedly expressed concerns about the efficacy of Merck & Company, Inc.'s (NYSE: 
Via Benzinga
Exposures Product Safety
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump. 
Via Benzinga
Diversifying Your Portfolio With Plant-Based Options
Investors see profit potential in the plant-based market due to rising consumer demand, ESG focus, and the growth of vegan products in various industries, including pharmaceuticals. However, market... 
Via Talk Markets
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Peering Into GSK's Recent Short Interest
Via Benzinga
Major Buyout Firms Eye Sanofi's Consumer Health Division Spinoff Valued Over $20B
Sanofi SA (NYSE: SNY) has reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over... 
Via Benzinga
Current Analysis: GSK Plc
In the pharmaceutical industry, GSK PLC ranks as one of the largest companies by total sales. 
Via Talk Markets
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
European Drug Regulator Recommends Approval Of GSK's Bone Marrow Cancer Med
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a posi 
Via Benzinga
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
From GSK plc
Via Business Wire
6 Nasdaq 100 Stocks Down 40% or More that Will Soar As Much 367%
Wall Street is forever optimistic about the future for stocks and pegs these seven Nasdaq 100 stocks as ready for supersonic growth 
Via InvestorPlace
GSK is a remedy for the winter investment blahs
Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
3 Healthcare Stocks Getting Help From the Aging Population
America's aging population needs chronic conditions treatments, and these healthcare stocks are growing in the quest for healing solutions. 
Via InvestorPlace
3 Top Dividend Stock Picks for Steady Income and Capital Appreciation
Conservative investors will benefit from these top dividend stock picks that are likely to generate significant returns. 
Via InvestorPlace
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
The company issued below-consensus sales views for 2023 and 2024. 
Via Investor's Business Daily
GSK Hikes Guidance On The Back Of Its Strong RSV Vaccine Launch
The company is rivaling Pfizer, which also gained approval this year for an RSV vaccine. 
Via Investor's Business Daily
GSK Lifts Annual Guidance Again Helped By Strong Launch Of RSV Vaccine, Steady Demand For Shingles Shot
GSK plc (NYSE: GSK) reported Q3 FY23 s 
Via Benzinga
Nasdaq, S&P 500 Futures Slide Ahead Of Fed Decision, Economic Data: Analyst Tells Why November Could Herald 'Good News'
U.S. stocks could start Wednesday's session lower as traders stay cautious ahead of the Fed decision and more earnings. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
GSK plc (NYSE: GSK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) have  
Via Benzinga
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
Hope for Endometrial Cancer - GSK Drug Proves Effective in Increasing Survival Rates
GSK plc (NYSE: GSK)  
Via Benzinga
GSK's Competitive Edge, Surpasses Pfizer in Respiratory Syncytial Virus Vaccine Sales
GSK (NYSE: GSK) has reportedly taken an early lead in the race for respiratory syncytial virus (RSV) vaccine dominance, surpassing Pfizer Inc (NYSE: PFE), which previously dominated the COVID-19... 
Via Benzinga
Exposures COVID-19
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe... 
From 23andMe, Inc.
Via GlobeNewswire
Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal
Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its... 
Via Talk Markets
3 Bill Gates Stocks to Buy for Billionaire-Like Returns
Microsoft and Berkshire Hathaway are the two most popular Bill Gates stocks. Investors know these three others far less. 
Via InvestorPlace
3 Deeply Undervalued Growth Stocks
As in 2022, the current downturn of stocks appears to be way overdone, making this a good time to buy undervalued growth stocks. 
Via InvestorPlace
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
From Alector, Inc.
Via GlobeNewswire
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
From GSK plc
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.